EMA Withdrawn: Exviera (dasabuvir sodium) — AbbVie Ltd

View source ↗

Summary

The European Medicines Agency has withdrawn Exviera (dasabuvir sodium) from the market; it was used to treat chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Exviera (dasabuvir)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis C, Chronic. MAH: AbbVie Ltd. Decision date: 12/08/2022. Accelerated assessment